Rate of vision loss in neovascular age-related macular degeneration explored
Purpose To explore decline in visual acuity in patients with neovascular age-related macular degeneration (n-AMD) awaiting intravitreal bevacizumab or ranibizumab treatment following initial diagnosis and after disease reactivation. Methods Retrospective analysis of 74 treatment-naïve patients (84 e...
Guardado en:
| Autores principales: | , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | Inglés |
| Publicado: |
2022
|
| Materias: | |
| Acceso en línea: | http://dx.doi.org/10.1007/s00417-014-2885-y http://hdl.handle.net/11086/28225 |
| Aporte de: |
| id |
I10-R141-11086-28225 |
|---|---|
| record_format |
dspace |
| institution |
Universidad Nacional de Córdoba |
| institution_str |
I-10 |
| repository_str |
R-141 |
| collection |
Repositorio Digital Universitario (UNC) |
| language |
Inglés |
| topic |
Age-related macular degeneration Bevacizumab Disease progression Health systems Patient safety Ranibizumab |
| spellingShingle |
Age-related macular degeneration Bevacizumab Disease progression Health systems Patient safety Ranibizumab Granero, Gladys E. De Santis, Mariana O. Juárez, Claudio P. Kelly, Simón P. Luna Pinto, José D. Real, Juan Pablo Palma, Santiago Daniel Rate of vision loss in neovascular age-related macular degeneration explored |
| topic_facet |
Age-related macular degeneration Bevacizumab Disease progression Health systems Patient safety Ranibizumab |
| description |
Purpose To explore decline in visual acuity in patients with neovascular age-related macular degeneration (n-AMD) awaiting intravitreal bevacizumab or ranibizumab treatment following initial diagnosis and after disease reactivation. Methods Retrospective analysis of 74 treatment-naïve patients (84 eyes) in two centers in Córdoba, Argentina. The time between treatment indication and intravitreal injection, and the changes in BCVA produced during this delay were studied in both periods. A linear regression model to search the impact of time on progression visual impairment was conducted.
Results In both periods, a significant reduction in vision occurred awaiting intravitreal injection. The longer the delay, the
greater the vision loss (R2=0.55 p<0.01) and the less improvement following treatment (Pearson coefficient −0.26).
The result of the model shows that the change in vision as a function of initial delay were best described by a polynomic
model with a mean loss of 5 letters in the first 3 weeks, a slowdown in the rate of change of VA, and a dependence of
visual acuity at the moment of diagnosis . The loss of visual acuity after reactivation shows the same behavior as at the
onset of the disease but independent of visual acuity prior to reactivation. Conclusion Visual loss awaiting injection intravitreal antiVEGF is clinically significant and with an asymptotic pattern, with early rapid loss of vision in both the onset of the disease
and the reactivation. Initiation of anti-VEGF treatment must be undertaken urgently, as should retreatment of disease activation to reduce visual loss. |
| format |
article |
| author |
Granero, Gladys E. De Santis, Mariana O. Juárez, Claudio P. Kelly, Simón P. Luna Pinto, José D. Real, Juan Pablo Palma, Santiago Daniel |
| author_facet |
Granero, Gladys E. De Santis, Mariana O. Juárez, Claudio P. Kelly, Simón P. Luna Pinto, José D. Real, Juan Pablo Palma, Santiago Daniel |
| author_sort |
Granero, Gladys E. |
| title |
Rate of vision loss in neovascular age-related macular degeneration explored |
| title_short |
Rate of vision loss in neovascular age-related macular degeneration explored |
| title_full |
Rate of vision loss in neovascular age-related macular degeneration explored |
| title_fullStr |
Rate of vision loss in neovascular age-related macular degeneration explored |
| title_full_unstemmed |
Rate of vision loss in neovascular age-related macular degeneration explored |
| title_sort |
rate of vision loss in neovascular age-related macular degeneration explored |
| publishDate |
2022 |
| url |
http://dx.doi.org/10.1007/s00417-014-2885-y http://hdl.handle.net/11086/28225 |
| work_keys_str_mv |
AT granerogladyse rateofvisionlossinneovascularagerelatedmaculardegenerationexplored AT desantismarianao rateofvisionlossinneovascularagerelatedmaculardegenerationexplored AT juarezclaudiop rateofvisionlossinneovascularagerelatedmaculardegenerationexplored AT kellysimonp rateofvisionlossinneovascularagerelatedmaculardegenerationexplored AT lunapintojosed rateofvisionlossinneovascularagerelatedmaculardegenerationexplored AT realjuanpablo rateofvisionlossinneovascularagerelatedmaculardegenerationexplored AT palmasantiagodaniel rateofvisionlossinneovascularagerelatedmaculardegenerationexplored |
| bdutipo_str |
Repositorios |
| _version_ |
1764820392017395712 |